quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:36:17·44d
ANALYSTRating
Alumis Inc. logo

Raymond James initiated coverage on Alumis with a new price target

ALMS· Alumis Inc.
Health Care
Original source

Companies

  • ALMS
    Alumis Inc.
    Health Care

Recent analyst ratings

  • Mar 11UpdateRaymond James$46.00
  • Feb 25UpdateStifel$44.00
  • Jan 21UpdateChardan Capital Markets$37.00
  • Jul 25UpdateWells Fargo$17.00
  • Jun 10UpdateGuggenheim$18.00
  • Jan 30UpdateOppenheimer$32.00

Related

  • INSIDER20d
    SEC Form 4 filed by Foresite Labs, Llc
  • INSIDER20d
    SEC Form 4 filed by Foresite Capital Management Vi Llc
  • INSIDER20d
    SEC Form 4 filed by Tananbaum James B.
  • SEC25d
    Alumis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR26d
    Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
  • SEC35d
    SEC Form S-3ASR filed by Alumis Inc.
  • SEC35d
    SEC Form 10-K filed by Alumis Inc.
  • SEC35d
    Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022